Get the Stockscreener App
9.85
1.40%
-0.14
After Hours:
9.88
0.03
+0.30%
Mind Medicine Inc stock is traded at $9.85, with a volume of 882.28K.
It is down -1.40% in the last 24 hours and up +0.92% over the past month.
Mind Medicine Inc. is a late-stage clinical biopharmaceutical company developing novel product candidates to treat brain health disorders. It is developing a pipeline of product candidates targeting neurotransmitter pathways that play key roles in brain health disorders. This includes explicitly pharmaceutically optimized product candidates derived from the psychedelic and empathogen drug classes, including MM120 and MM402, as its key product candidates. The MM120 is a proprietary, pharmaceutically optimized form of lysergide D-tartrate that is being developed to treat generalized anxiety disorder and clinical depressive disorder, and the MM402 is a proprietary form of the R-enantiomer of 3,4-methylenedioxymethamphetamine (MDMA), being developed to treat autism spectrum disorder (ASD).
See More
Previous Close:
$9.99
Open:
$9.95
24h Volume:
882.28K
Relative Volume:
0.74
Market Cap:
$749.47M
Revenue:
$11.40B
Net Income/Loss:
$-95.73M
P/E Ratio:
-4.0204
EPS:
-2.45
Net Cash Flow:
$-64.37M
1W Performance:
+4.23%
1M Performance:
+0.92%
6M Performance:
+47.01%
1Y Performance:
+58.11%
1-Day Range:
$9.82
$10.12
1-Week Range:
$9.25
$11.02
52-Week Range:
$4.70
$11.02
Mind Medicine Inc Stock (MNMD) Company Profile
Name
Mind Medicine Inc
Sector
Industry
Phone
212-220-6633
Address
ONE WORLD TRADE CENTER, NEW YORK
Compare MNMD with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
MNMD
Mind Medicine Inc
|
9.85 | 760.12M | 11.40B | -95.73M | -64.37M | -2.45 |
|
VRTX
Vertex Pharmaceuticals Inc
|
389.08 | 99.27B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
586.96 | 62.28B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
454.18 | 59.14B | 2.46B | -319.09M | -52.09M | -2.47 |
|
ARGX
Argen X Se Adr
|
707.96 | 43.34B | 3.06B | 1.28B | 447.35M | 21.30 |
|
ONC
Beone Medicines Ltd Adr
|
300.14 | 36.72B | 3.81B | -644.79M | -669.77M | -6.24 |
Mind Medicine Inc Stock (MNMD) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Aug-04-25 | Resumed | Oppenheimer | Outperform |
| Jan-28-25 | Initiated | Evercore ISI | Outperform |
| Dec-20-24 | Initiated | Chardan Capital Markets | Buy |
| Oct-14-24 | Resumed | Leerink Partners | Outperform |
| Jul-24-24 | Initiated | ROTH MKM | Buy |
| May-29-24 | Initiated | Robert W. Baird | Outperform |
| Apr-15-24 | Initiated | Leerink Partners | Outperform |
| Dec-05-23 | Initiated | Canaccord Genuity | Buy |
| Dec-09-22 | Resumed | ROTH Capital | Buy |
| Nov-16-22 | Initiated | RBC Capital Mkts | Outperform |
| Aug-26-22 | Initiated | Oppenheimer | Outperform |
| Aug-10-22 | Initiated | Cantor Fitzgerald | Overweight |
| May-04-22 | Initiated | ROTH Capital | Buy |
| Jun-28-21 | Initiated | Maxim Group | Buy |
View All
Mind Medicine Inc Stock (MNMD) Latest News
Is Mind Medicine (MindMed) Inc. forming a bottoming base2025 Momentum Check & Free Community Supported Trade Ideas - Newser
Intraday pattern recognizer results for Mind Medicine (MindMed) Inc.July 2025 Sentiment & Safe Entry Point Alerts - Newser
Is Mind Medicine (MindMed) Inc. stock entering bullish territoryDay Trade & Weekly Top Stock Performers List - Newser
Published on: 2025-08-27 04:57:54 - Newser
Mind Medicine (MindMed) Inc. stock outlook for YEAR2025 Market Trends & Verified Entry Point Detection - Newser
What technical models suggest about Mind Medicine (MindMed) Inc.’s comebackJuly 2025 Breakouts & Weekly High Potential Stock Alerts - Newser
Real time social sentiment graph for Mind Medicine (MindMed) Inc.Quarterly Trade Report & High Conviction Investment Ideas - Newser
Using RSI to spot recovery in Mind Medicine (MindMed) Inc.Index Update & Technical Pattern Based Buy Signals - Newser
What institutional flow reveals about Mind Medicine (MindMed) Inc.July 2025 Final Week & Capital Protection Trading Alerts - Newser
How to use Fibonacci retracement on Mind Medicine (MindMed) Inc.2025 Dividend Review & Technical Entry and Exit Alerts - Newser
How to build a custom watchlist for Mind Medicine (MindMed) Inc.Layoff News & Weekly Top Stock Performers List - Newser
Long term hold vs stop loss in Mind Medicine (MindMed) Inc.Profit Target & Fast Gaining Stock Strategy Reports - Newser
Historical volatility pattern of Mind Medicine (MindMed) Inc. visualizedJuly 2025 Price Swings & High Win Rate Trade Tips - Newser
When is the best time to exit Mind Medicine (MindMed) Inc.Trade Analysis Report & Verified Swing Trading Watchlists - Newser
Published on: 2025-08-26 08:34:56 - Newser
Exit strategy if you’re trapped in Mind Medicine (MindMed) Inc.Options Play & Technical Pattern Alert System - Newser
Will breakout in Mind Medicine (MindMed) Inc. lead to full recoveryQuarterly Profit Report & Weekly Market Pulse Updates - Newser
What MACD signals say about Mind Medicine (MindMed) Inc.2025 Investor Takeaways & Growth Focused Stock Pick Reports - Newser
Published on: 2025-08-25 23:08:05 - Newser
How Mind Medicine (MindMed) Inc. stock performs during market volatilityJuly 2025 Price Swings & Daily Chart Pattern Signal Reports - Newser
Why Mind Medicine (MindMed) Inc. is moving today2025 Market Outlook & Community Supported Trade Ideas - Newser
Reversal indicators forming on Mind Medicine (MindMed) Inc. stock2025 AllTime Highs & Detailed Earnings Play Strategies - Newser
Bollinger Bands Expand on Mind Medicine (MindMed) Inc. — Volatility AheadMarket Risk Analysis & Expert Curated Trade Setups - 더경남뉴스
Published on: 2025-08-23 04:23:41 - classian.co.kr
Mind Medicine upgraded at Oppenheimer on lead asset - MSN
What makes Mind Medicine (MindMed) Inc. stock price move sharplyTrade Signal Summary & Long-Term Safe Investment Plans - Newser
Price momentum metrics for Mind Medicine (MindMed) Inc. explainedWeekly Earnings Recap & Long-Term Investment Growth Plans - Newser
Advanced analytics toolkit walkthrough for Mind Medicine (MindMed) Inc.Market Performance Report & AI Forecast for Swing Trade Picks - Newser
H.C. Wainwright Reiterates Buy Rating for Mind Medicine with $55 Price Target - AInvest
What to expect from Mind Medicine (MindMed) Inc. in the next 30 daysWeekly Trade Recap & High Return Trade Opportunity Guides - Newser
Pattern recognition hints at Mind Medicine (MindMed) Inc. upside2025 Earnings Surprises & Daily Technical Stock Forecast Reports - Newser
Enveric Biosciences: Poised to Outshine Traditional Psychedelic Targets - microdose.buzz
Is Mind Medicine (MindMed) Inc. Forming a Consolidation BaseTreasury Yields & Breakout Confirmation Trade Signals - newsimpact.co.kr
What data driven models say about Mind Medicine (MindMed) Inc.’s futureQuarterly Profit Summary & Weekly Watchlist of Top Performers - Newser
Mind Medicine (MindMed) Inc. Facing Inflection Point in Trend Analysis2025 Valuation Update & Momentum Based Trading Signals - 선데이타임즈
Mind Medicine (MindMed) Inc. Crosses 200 Day MA — Signal or NoiseWeekly Gains Summary & Detailed Earnings Play Alerts - 선데이타임즈
RSI Crosses Above 30 for Mind Medicine (MindMed) Inc. — Reversal in SightJuly 2025 News Drivers & Weekly Breakout Watchlists - 선데이타임즈
1 Reason to Buy MindMed (MNMD) - AOL.com
If You'd Invested $1,000 in Mind Medicine (MNMD) Stock 5 Years Ago, Here's How Much You'd Have Today - MSN
How to build a dashboard for Mind Medicine (MindMed) Inc. stockHigh Accuracy Trade Setup Identification - Newser
MindMed Announces New Employee Inducement Grants - Business Wire
MindMed (MNMD) Q2 2025 Earnings Call Transcript - AOL.com
MindMed Reports Strong Q2 2025 Results - The Motley Fool
Mind Medicine (MindMed) Inc.'s (NASDAQ:MNMD) large institutional owners must be happy as stock continues to impress, up 17% over the past week - simplywall.st
Mind Medicine (MindMed) (NASDAQ:MNMD) Earns Outperform Rating from Analysts at Oppenheimer - MarketBeat
MindMed Reports Strong Phase 3 Trial Progress and Leadership Appointment - The Globe and Mail
Mind Medicine Inc Stock (MNMD) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.98%
8.06%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):